Skip Ribbon Commands
Skip to main content
Sign In
{{'GLOBAL_MESSAGE_OR' | translate}}
{{'ELOQUA_BANNER_ACCEPT' | translate}}
{{'ELOQUA_BANNER_DECLINE' | translate}}
COVID-19 Response & Business Continuity
Statement from Terumo BCT

Terumo BCT and Terumo Corporation, our parent company, are closely monitoring the current outbreak of coronavirus disease (COVID-19). Our preparations and response are guided by our mission: Contributing to Society Through Healthcare.

We are actively planning based on three principles:

  • First, our utmost priority is the continued health and well-being of our 7,100 employees worldwide.
  • Second, we are exercising maximum effort to maintain a stable supply of products to meet healthcare needs.
  • Finally, we are actively engaged in and contributing to the global efforts for the prevention and treatment of COVID-19.

Read More

Business Continuity Information

Terumo BCT has strong business continuity plans to help ensure continued availability of our products that are used to treat critically ill patients and that collect and process blood and blood products. We know a safe, sustainable and readily available supply of blood is vital to those with serious conditions and diseases.

Business Continuity Infographic

Update to our Customers, Terumo BCT Global Supply Chain and Logistics in Response to the Novel Coronavirus (COVID-19) Pandemic – 30 March 2020

We can confirm that there is little disruption to our supply chain as a result of the pandemic. We have implemented safety precautions at our factories to ensure social distancing to protect our associates and are currently operating at sufficient levels to meet current demand.     Read More

COVID-19 World Health Organization resources

Read More


{{'SEARCH_MODAL_TITLE' | translate }}
{{'SEARCH_MODAL_OR' | translate }}

{{'SEARCH_MODAL_BROWSE' | translate }}
{{$index+1}}. {{s.label}}